Clinical trial
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
NCT00490516 · ACADIA Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00490516 |
|---|---|
| Title | ACP-104 in Acutely Psychotic Subjects With Schizophrenia |
| Official title | A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia |
| Lead sponsor | ACADIA Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | ACP-104, Placebo |
| Enrollment | 247 |
| Start date | Jun 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 22, 2007 |
| Last update posted | Jan 20, 2025 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: